Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca has submitted market authorization application to the European Medicines Agency for oral anticancer drug, gefitinib, as a treatment for locally advanced or metastatic non-small cell lung cancer in patients who have been pre-treated with platinum-containing chemotherapy.
Subscribe to our email newsletter
The application is based on data from the Phase III Interest study, which showed that patients with pre-treated advanced non-small cell lung cancer (NSCLC) who received gefitinib had non-inferior overall survival to those treated with intravenous chemotherapy (docetaxel).
AstraZeneca said that gefitinib had a more favorable tolerability profile than docetaxel and significantly more patients receiving gefitinib had an improvement in quality of life.